Zymeworks has appointed Brian Cherry to its Board of Directors effective January 12, 2026, expanding the Board to nine members following a deliberate reduction from twelve directors over the past year. Mr. Cherry brings over 25 years of private equity and growth equity experience, having led investments totaling more than $25 billion in enterprise value across healthcare, industrials, business services, financial services and consumer products. His prior roles include Managing Partner at Oak Hill Capital and board service at over a dozen private and public companies, the U.S. Air Force Academy Foundation and the University of Pennsylvania’s Undergraduate Financial Aid Leadership Council. This appointment follows the addition of Oleg Nodelman, Greg Ciongoli and Robert E. Landry to the Board within the last twelve months, underscoring Zymeworks’ focus on aligning board expertise with its corporate strategy.

Effective February 1, 2026, Dr. Sabeen Mekan will assume the role of Chief Medical Officer, overseeing clinical development, regulatory affairs, pharmacovigilance and clinical operations. Concurrently, Mark Hollywood has been promoted to Executive Vice President and Chief Operating Officer, expanding his remit beyond Technology and Manufacturing Operations, Quality and Alliance/Program Management. Dr. Jeff Smith, the current CMO, will retire on January 31, 2026 and continue in an advisory capacity during the transition. Leone Patterson (Chief Financial and Business Officer) and Daniel Dex (General Counsel) will depart in Q1 2026, prompting a comprehensive search for a permanent CFO; in the interim, Kenneth Galbraith serves as Acting Chief Financial Officer.

Reflecting its commitment to cultivating leaders from within, Zymeworks has promoted or appointed five senior vice presidents and vice presidents across key functions. Laura O’Connor becomes Senior Vice President and Chief Human Resources Officer, Bijal Desai is named Senior Vice President, Finance, and Dr. Lindsey Foulkes assumes the role of Senior Vice President, Corporate Development and Strategy. On the vice president level, Dr. Charles Chen will lead Translational Sciences, while Shrinal Inamdar heads Investor Relations. These appointments underscore the company’s emphasis on building organizational depth to execute its multifunctional biotherapeutics strategy.